Memorial Sloan Kettering Cancer Center: Neuroblastoma trials

The registry lists 49 Neuroblastoma studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 5 are open to participants now and 12 have results posted.

Early Phase 1 3Phase 1 14Phase 2 24No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With NeuroblastomaRecruitingNCT06528496Phase 2
• A Study of a Vaccine in Combination With Beta-glucan in People With NeuroblastomaRecruitingNCT06057948Phase 2
• A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With NeuroblastomaRecruitingNCT04936529Phase 2
• Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical OutcomeRecruitingNCT00588068
• Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or ParagangliomaRecruitingNCT00107289Phase 2
• Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma PatientsCompletedNCT02924324Not applicableResults posted
• Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk NeuroblastomaCompletedNCT02100930Not applicableResults posted
• Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and NeuroblastomaCompletedNCT01492673Phase 2Results posted
• 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone MarrowCompletedNCT01183897Phase 2Results posted
• 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk NeuroblastomaTerminatedNCT01183884Phase 2Results posted
• 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk NeuroblastomaCompletedNCT01183429Phase 2Results posted
• High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell TransplantationCompletedNCT01183416Phase 2Results posted
• Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory NeuroblastomaCompletedNCT01114555Phase 2Results posted
• Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9TerminatedNCT00582608Not applicableResults posted
• Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal CancerCompletedNCT00445965Phase 2Results posted
• Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With NeuroblastomaCompletedNCT00072358Phase 2Results posted
• Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid TumorsCompletedNCT00024258Phase 2Results posted
• A Study of Avutometinib for People With Solid Tumor CancersActive, not recruitingNCT06104488Phase 1
• 131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young AdultsNo longer availableNCT05064306
• A Study of N9 Chemotherapy in Children With NeuroblastomaActive, not recruitingNCT04947501Early Phase 1
• Naxitamab and GM-CSF in People With NeuroblastomaNo longer availableNCT04501757
• Study of Chemoimmunotherapy for High-Risk NeuroblastomaActive, not recruitingNCT03189706Early Phase 1
• A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk NeuroblastomaCompletedNCT03033303Phase 2
• Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk NeuroblastomaCompletedNCT02650648Phase 1
• PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot StudyActive, not recruitingNCT02307630Not applicable
• Local Control With Reduced-dose Radiotherapy for High-Risk NeuroblastomaCompletedNCT02245997Early Phase 1
• Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk NeuroblastomaActive, not recruitingNCT01757626Phase 1/2
• Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid TumorsCompletedNCT01662804Phase 1
• Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical ImagingCompletedNCT01482741
• Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive TumorsCompletedNCT01419834Phase 1
• Genomic Structural Variation in Cancer SusceptibilityActive, not recruitingNCT00996710
• Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk NeuroblastomaCompletedNCT00911560Phase 1/2
• Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk NeuroblastomaCompletedNCT00877110Phase 1
• Prevalence+Significance of Paraneoplastic Autoantibodies in Many CancersCompletedNCT00608452
• Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic NeuroblastomaCompletedNCT00492167Phase 1
• Ethanol-Lock Treatment in Preventing Central Venous Catheter Infections in Patients With High-Risk NeuroblastomaCompletedNCT00471679Phase 1
• Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory NeuroblastomaCompletedNCT00450827Phase 1
• Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed NeuroblastomaCompletedNCT00450307Phase 1
• Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous TreatmentCompletedNCT00089258Phase 2
• Multiple Therapies in Treating Patients With Advanced NeuroblastomaCompletedNCT00040872Phase 2
• Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic NeuroblastomaCompletedNCT00037011Phase 1
• Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With NeuroblastomaCompletedNCT00004110Phase 2
• Rebeccamycin Analog in Treating Children With Relapsed or Refractory NeuroblastomaCompletedNCT00003737Phase 2
• Monoclonal Antibody A1G4 Plus BCG in Treating Patients With CancerCompletedNCT00003023Phase 1
• Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal CancerCompletedNCT00003022Phase 1
• Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With NeuroblastomaCompletedNCT00002634Phase 2
• Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced NeuroblastomaCompletedNCT00002560Phase 2
• Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare CancerCompletedNCT00002515Phase 2
• Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second RemissionCompletedNCT00002458Phase 2